Radioprotectors and mitigators of radiation-induced normal tissue injury

Deborah Citrin, Ana P. Cotrim, Fuminori Hyodo, Bruce J. Baum, Murali C. Krishna, James B. Mitchell

    Research output: Contribution to journalArticlepeer-review

    366 Citations (Scopus)


    Radiation is used in the treatment of a broad range of malignancies. Exposure of normal tissue to radiation may result in both acute and chronic toxicities that can result in an inability to deliver the intended therapy, a range of symptoms, and a decrease in quality of life. Radioprotectors are compounds that are designed to reduce the damage in normal tissues caused by radiation. These compounds are often antioxidants and must be present before or at the time of radiation for effectiveness. Other agents, termed mitigators, may be used to minimize toxicity even after radiation has been delivered. Herein, we review agents in clinical use or in development as radio protectors and mitigators of radiation-induced normal tissue injury. Few agents are approved for clinical use, but many new compounds show promising results in preclinical testing.

    Original languageEnglish
    Pages (from-to)360-371
    Number of pages12
    Issue number4
    Publication statusPublished - Apr 2010

    All Science Journal Classification (ASJC) codes

    • Oncology
    • Cancer Research


    Dive into the research topics of 'Radioprotectors and mitigators of radiation-induced normal tissue injury'. Together they form a unique fingerprint.

    Cite this